Rapid progress in the field of pharmacotherapy resulted in significant changes in the recommendations regarding the treatment of psoriatic arthritis in recent years. The latest guidelines for the treatment of psoriatic arthritis are the recommendations of the European League Against Rheumatism (EULAR) from 2019. and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) from 2021. A wide range of currently available modern drugs creates great opportunities to select an effective therapy individually for each patient. Psoriatic arthritis is a very heterogeneous disease, therefore the choice of a specific drug should be tailored to the needs of a given patient. When making therapeutic decisions, it is crucial to determine the dominant musculoskeletal symptoms, but the coexistence of extra-articular symptoms, such as skin lesions and nail involvement, as well as other accompanying conditions, should also be taken into account. In this study, we present current recommendations regarding the treatment of psoriatic arthritis in Poland, with particular emphasis on biologic therapies.
No takes yet. Share an insight, caveat, or question.
Sikorska et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: